These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 33909185)

  • 1. JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold?
    Akkoc N; Khan MA
    Curr Rheumatol Rep; 2021 Apr; 23(6):34. PubMed ID: 33909185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Axial Spondyloarthritis - Insights into Upadacitinib.
    Braun J; Kiltz U; Baraliakos X
    Drug Des Devel Ther; 2022; 16():3609-3620. PubMed ID: 36268520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib for the treatment of active ankylosing spondylitis in adults.
    Mohanakrishnan R; Beier S; Deodhar A
    Expert Rev Clin Immunol; 2022 Mar; 18(3):273-280. PubMed ID: 35152808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
    Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2022 Feb; 81(1):71-76. PubMed ID: 33340056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
    van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J
    Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.
    van der Heijde D; Deodhar A; Baraliakos X; Brown MA; Dobashi H; Dougados M; Elewaut D; Ellis AM; Fleurinck C; Gaffney K; Gensler LS; Haroon N; Magrey M; Maksymowych WP; Marten A; Massow U; Oortgiesen M; Poddubnyy D; Rudwaleit M; Shepherd-Smith J; Tomita T; Van den Bosch F; Vaux T; Xu H
    Ann Rheum Dis; 2023 Apr; 82(4):515-526. PubMed ID: 36649967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upadacitinib for the treatment of adults with active non-radiographic axial spondyloarthritis (nr-axSpA).
    Fukui S; Kawaai S; Sawada H; Kishimoto M
    Expert Rev Clin Immunol; 2024 Feb; 20(2):141-153. PubMed ID: 37955181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
    van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
    Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
    Keeling S; Maksymowych WP
    Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics and exposure-response analyses for efficacy and safety of upadacitinib in patients with axial spondyloarthritis.
    Bhatnagar S; Eckert D; Stodtmann S; Song IH; Wung P; Liu W; Mohamed MF
    Clin Transl Sci; 2024 Feb; 17(2):e13733. PubMed ID: 38344875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Efficacy and Safety of Janus Kinase Inhibitors and Secukinumab in Patients with Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis.
    Lee YH
    Pharmacology; 2022; 107(11-12):537-544. PubMed ID: 35817017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
    Ortolan A; Webers C; Sepriano A; Falzon L; Baraliakos X; Landewé RB; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):142-152. PubMed ID: 36261247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
    Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
    Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Deodhar A; Van den Bosch F; Poddubnyy D; Maksymowych WP; van der Heijde D; Kim TH; Kishimoto M; Blanco R; Duan Y; Li Y; Pangan AL; Wung P; Song IH
    Lancet; 2022 Jul; 400(10349):369-379. PubMed ID: 35908570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of axial spondyloarthritis: an update.
    Danve A; Deodhar A
    Nat Rev Rheumatol; 2022 Apr; 18(4):205-216. PubMed ID: 35273385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK Inhibitors for the Treatment of Axial Spondyloarthritis.
    Klavdianou K; Papagoras C; Baraliakos X
    Mediterr J Rheumatol; 2023 Jun; 34(2):129-138. PubMed ID: 37654636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of upadacitinib for the treatment of axial spondyloarthritis.
    George N; Liew JW; Dubreuil M
    Immunotherapy; 2023 Oct; 15(15):1227-1237. PubMed ID: 37675498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Upadacitinib for Axial Spondyloarthritis: A Systematic Review and Meta-Analysis.
    Ali AHG; Elganady A; Hindawi MD; Mousa AIA; Eldeeb HA; Fatiem AR; Skopina Y
    Curr Rheumatol Rev; 2024 Aug; ():. PubMed ID: 39162272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.